The US budget reconciliation bill includes pivotal biotech provisions supporting innovation and patient access. Key components involve the ORPHAN Cures Act fixing rare disease drug exemptions in the Inflation Reduction Act, immediate tax deductions for R&D expenditures, and preservation of the Orphan Drug Tax Credit. Collectively, the measures aim to sustain robust research ecosystems while improving affordability, balancing innovation incentives with healthcare policy goals.